Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and SafetyNicholas A. Vitanza, Julie R. Park, Rebecca Gardner et al.|Cancer Discovery|2022Cited by 277
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trialNicholas A. Vitanza, Michael C. Jensen, Rebecca Ronsley et al.|Nature Medicine|2025Cited by 154
Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosingJacob Appelbaum, Michael C. Jensen, April E. Price et al.|Journal of Clinical Investigation|2024Cited by 51
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid TumorsNavin Pinto, Julie R. Park, Catherine M. Albert et al.|Journal of Clinical Oncology|2024Cited by 46
Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safetyNicholas A. Vitanza, Julie R. Park, Rebecca Ronsley et al.|Neoplasia|2023Cited by 35